A simple table lookup method for PET/CT partial volume correction using a point-spread function in diagnosing lymph node metastasis

Sakaguchi, Yuichi; Mizoguchi, Noriko; Mitsumoto, Tatsuya; Mitsumoto, Katsuhiko; Himuro, Kazuhiko; Ohya, Nobuyoshi; Kaneko, Koichiro; Baba, Shingo; Abe, Koichiro; Onizuka, Yoshihiko; Sasaki, Masayuki

doi:10.1007/s12149-010-0401-y

Cited by 15 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radioactivity distribution in the liver was homogeneous; therefore, a large representative region of interest was deemed sufficient for analytical purposes. Data (percentage injected dose per gram of tissue [ID/g]) were corrected for partial volume effect and spillover (12) by using calibration factors obtained from scanning a cylinder that contained phantoms of different sizes, with phantom-to-background activity ratios ranging from 3:1 to 25:1 (13). Image quality was compared at different time points after injection to determine whether imaging at early time points was feasible.…”

Section: Micro-pet Image Data Analysismentioning

confidence: 99%

Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope

et al. 2015

View full text Add to dashboard Cite

Purpose:To develop and compare three copper 64 ( 64 Cu)-labeled antibody fragments derived from a CA6-targeting antibody (huDS6) as immuno-positron emission tomography (immuno-PET)-based companion diagnostic agents for an antibody-drug conjugate by using huDS6. Materials and Methods:Three antibody fragments derived from huDS6 were produced, purified, conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and evaluated in the following ways: (a) the affinity of the fragments and the DOTA conjugates was measured via flow cytometry, (b) the stability of the labeled fragments was determined ex vivo in human serum over 24 hours, and (c) comparison of the in vivo imaging potential of the fragments was evaluated in mice bearing subcutaneous CA6-positive and CA6-negative xenografts by using serial PET imaging and biodistribution. Isotype controls with antilysozyme and anti-DM4 B-Fabs and blocking experiments with an excess of either B-Fab or huDS6 were used to determine the extent of the antibody fragment 64 Cu-DOTA-B-Fab binding specificity. Immunoreactivity and tracer kinetics were evaluated by using cellular uptake and 48-hour imaging experiments, respectively. Statistical analyses were performed by using t tests, one-way analysis of variance, and Wilcoxon and Mann-Whitney tests. Results:The antibody fragment 64Cu-DOTA-B-Fab was more than 95% stable after 24 hours in human serum, had an immunoreactivity of more than 70%, and allowed differentiation between CA6-positive and CA6-negative tumors in vivo as early as 6 hours after injection, with a 1.7-fold uptake ratio between tumors. Isotype and blocking studies experiments showed tracer-specific uptake in antigen-positive tumors, despite some nonspecific uptake in both tumor models. Conclusion:Three antibody fragments were produced and examined as potential companion diagnostic agents. 64 Cu-DOTA-BFab is a stable and effective immuno-PET tracer for CA6 imaging in vivo.q RSNA, 2015

show abstract

Section: Micro-pet Image Data Analysismentioning

confidence: 99%

Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope

et al. 2015

View full text Add to dashboard Cite

show abstract

“…and type of lesions Lesion sizes (mm) a T/N/M Cut-off Non-PVC PVC Method of staging Effect on test performance? [ 25 ] 178 NSCLC NS Range 18 ± 5 to 44 ± 20 TNM NA Imaging / surgery / pathology NA [ 26 ] 7 Thyroid (mLN) 15 M, 24 B NS N Data-driven 4.0 10.0 Imaging / pathology Sens = 100% Spec ↑ 92 to 100% [ 27 ] 52 Breast NS NS N NS NS Imaging Sens ↑ 75 to 86% Spec ↓ 87 to 83% [ 28 ] 58 NSCLC 201 7.2 ± 1.7 (<10 mm), 19.2 ± 1.05 (≥10 mm) N NA Pathology / imaging / clinical Sens ↑ 78 to 97% Spec ↓ 71 to 58% [ 29 ] 35 Lung NS 30 (range 8–79) TNM NA Imaging / pathology NA [ 30 ] 50 Breast (mLN) NS 8.2 ± 4.3 N NA Pathology Sens ↑ 76 to 85% Spec ↓ 75 to 69% [ 31 ] 32 HNSCC (mLN) 18 M, 39 B 1.14 ± 1.38 mL (M), 0.64 ± 0.93 mL (B) N Data-driven NS Pathology Sens ↑ 57 to 64% Spec ↑ 71 to 76% …”

Section: Resultsmentioning

confidence: 99%

“…In non-small cell lung cancer (NSCLC) patients the association between primary tumor SUVmax and overall TNM stage disappeared after PVC [ 25 ]. For nodal staging using SUV, non-significant trends of increased accuracy for breast, head and neck squamous cell, and thyroid cancer (from 80%, 66% and 95% to 84%, 71% and 100%, respectively) [ 26 , 27 , 31 ], and decreased accuracy for nasopharyngeal and prostate cancer (from 84% and 85% to 73% and 80%, respectively) were observed [ 32 , 33 ]. The study investigating accuracy of nodal staging of nasopharyngeal cancer did observe a large increase in accuracy, from 14 to 71%, when stratifying for lesion size (6–7 mm diameter) [ 32 ].…”

Section: Resultsmentioning

confidence: 99%

Impact of partial-volume correction in oncological PET studies: a systematic review and meta-analysis

Cysouw

Krämer

Schoonmade

et al. 2017

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

PurposePositron-emission tomography can be useful in oncology for diagnosis, (re)staging, determining prognosis, and response assessment. However, partial-volume effects hamper accurate quantification of lesions <2–3× the PET system’s spatial resolution, and the clinical impact of this is not evident. This systematic review provides an up-to-date overview of studies investigating the impact of partial-volume correction (PVC) in oncological PET studies.MethodsWe searched in PubMed and Embase databases according to the PRISMA statement, including studies from inception till May 9, 2016. Two reviewers independently screened all abstracts and eligible full-text articles and performed quality assessment according to QUADAS-2 and QUIPS criteria. For a set of similar diagnostic studies, we statistically pooled the results using bivariate meta-regression.ResultsThirty-one studies were eligible for inclusion. Overall, study quality was good. For diagnosis and nodal staging, PVC yielded a strong trend of increased sensitivity at expense of specificity. Meta-analysis of six studies investigating diagnosis of pulmonary nodules (679 lesions) showed no significant change in diagnostic accuracy after PVC (p = 0.222). Prognostication was not improved for non-small cell lung cancer and esophageal cancer, whereas it did improve for head and neck cancer. Response assessment was not improved by PVC for (locally advanced) breast cancer or rectal cancer, and it worsened in metastatic colorectal cancer.ConclusionsThe accumulated evidence to date does not support routine application of PVC in standard clinical PET practice. Consensus on the preferred PVC methodology in oncological PET should be reached. Partial-volume-corrected data should be used as adjuncts to, but not yet replacement for, uncorrected data.Electronic supplementary materialThe online version of this article (doi:10.1007/s00259-017-3775-4) contains supplementary material, which is available to authorized users.

show abstract

“…The details of this method have been previously described. 19,20 Based on the phantom studies, recovery coefficient (RC) curves for each device were first generated. The RC of each sphere was expressed as the ratio of the maximum radioactivity of each sphere to that of the 37 mm sphere for each SB ratio.…”

Section: Generation Of Lookup Table For Pvcmentioning

confidence: 99%

“…Although several methods of performing partial volume correction (PVC) have been proposed, [15][16][17][18] we previously developed a simple table lookup method for PVC. 19,20 This method is easily applicable to different PET scanners and protocols. However, the application of this method in clinical examinations has not been performed using different PET scanners.…”

mentioning

confidence: 99%

Standardization of dual time point [18F] 2-Deoxy-2-fluoro-D-glucose-positron emission tomography performed with different positron emission tomography scanners using partial volume correction

Mikasa¹,

Akamatsu²,

Taniguchi³

et al. 2015

RRNM

Self Cite

View full text Add to dashboard Cite

Introduction:The aim of this study was to examine the possibility of using the partial volume correction (PVC) to standardize dual time point [18F] 2-Deoxy-2-fluoro-D-glucose (FDG)-positron emission tomography (PET) studies with two PET scanners. Materials and methods: One hundred and thirteen lesions from 96 breast cancer patients were examined. FDG-PET scans were performed at both 60 and 120 minutes after FDG injection using different PET scanners. The maximum standardized uptake values (SUV max s) were measured at both time points (SUV max 1 and SUV max 2) and the percent change in the SUV max (∆%SUV max ) between the two time points was calculated. PVC was performed using a look-up table generated based on the recovery coefficient curves and point spread function of each scanner. Results: The SUV max 1, the SUV max 2, and the ∆%SUV max were 5.67±4.45, 5.15±4.29, and -9.30%±20.54%, respectively. After PVC, all parameters significantly increased to 10.44±5.55, 10.23±5.77, and -1.15%±21.66%, respectively. In addition, the number of lesions with a positive ∆%SUV max increased after PVC, from 26.5% to 40.7%. Conclusion: PVC of the SUV max is considered to be useful for standardizing dual time point FDG-PET studies in patients with breast cancer performed using different PET scanners. This method is also expected to be useful for standardizing multicenter PET studies.

show abstract

A simple table lookup method for PET/CT partial volume correction using a point-spread function in diagnosing lymph node metastasis

Cited by 15 publications

References 13 publications

Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope

Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope

Impact of partial-volume correction in oncological PET studies: a systematic review and meta-analysis

Standardization of dual time point [18F] 2-Deoxy-2-fluoro-D-glucose-positron emission tomography performed with different positron emission tomography scanners using partial volume correction

Contact Info

Product

Resources

About